Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 2/20 | 0.77 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.77 |
| ▸ | FLT4 | P35916 | 1/20 | 0.77 |
| ▸ | KDR | P35968 | 1/20 | 0.77 |
| ▸ | ILK | Q13418 | 1/20 | 0.77 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.77 |
| ▸ | RAF1 | P04049 | 4/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.47 |
| ▸ | BRAF | P15056 | 6/20 | 0.47 |
| ▸ | ABL1 | P00519 | 4/20 | 0.39 |
| ▸ | BCR | P11274 | 3/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | DHODH | Q02127 | 1/20 | 0.38 |
| ▸ | CSF1R | P07333 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4035661 | 0.90 | KDR (0.80) | KITPDGFRBFLT4KDRILK | |
| SCHEMBL2200989 | 0.90 | KDR (0.82) | KITPDGFRBFLT4KDRILK | |
| SCHEMBL4035178 | 0.89 | KIT (0.84) | KITPDGFRBFLT4KDRILK | |
| SCHEMBL4037825 | 0.89 | KIT (0.86) | KITPDGFRBFLT4KDRILK | |
| SCHEMBL4037126 | 0.88 | KIT (0.85) | KITPDGFRBFLT4KDRILK | |
| Telatinib SCHEMBL29353813 | 0.87 | KDR (1.00) | KITPDGFRBFLT4KDRILK | |
| SCHEMBL4035689 | 0.87 | KIT (0.84) | KITPDGFRBFLT4KDRILK | |
| Telatinib SCHEMBL1250560 | 0.87 | KDR (1.00) | KITPDGFRBFLT4KDRILK | |
| Telatinib SCHEMBL29884336 | 0.87 | KDR (1.00) | KITPDGFRBFLT4KDRILK | |
| SCHEMBL4037772 | 0.87 | KDR (0.83) | KITPDGFRBFLT4KDRILK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1228063-B1 | SUBSTITUTED PYRIDINES AND PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | BAYER CORP (US) | 2009-02-11 | — | — | EP | claimed |
| US-20050019424-A1 | Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives | BAYER HEALTHCARE LLC | 2005-01-27 | — | — | US | claimed |
| EP-1467736-A2 | ANTI-ANGIOGENESIS COMBINATION THERAPIES COMPRISING PYRIDAZINE OR PYRIDINE DERIVATIVES | Bayer Pharmaceuticals Corporation (US) | 2004-10-20 | — | — | EP | claimed |
| WO-2003059354-A2 | ANTI-ANGIOGENESIS COMBINATION THERAPIES COMPRISING PYRIDAZINE OR PYRIDINE DERIVATIVES | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-07-24 | — | — | WO | claimed |
| US-7511037-B2 | N-[[4-fluoro-2-(5-methy-1H-1,2,4-triazol-1-yl)phenyl]methyl]-4-,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo-pyrimido[2,1-c][1,4]oxazine-2-carboxamide as an HIV integrase inhibitor | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-03-31 | — | — | US | disclosed |
| US-7491819-B1 | N-[4-Fluorophenyl)methyl]-4,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo-pyrimido[2,1-c][1,4]oxazine-2-carboxamide as an HIV integrase inhibitor | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-02-17 | — | — | US | disclosed |
| EP-1749011-B1 | BICYCLIC HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-10-29 | — | — | EP | disclosed |
| US-7176196-B2 | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-13 | — | — | US | disclosed |
| US-7157447-B2 | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
| US-20060276466-A1 | Bicyclic heterocycles as HIV integrase inhibitors | NAIDU B N | 2006-12-07 | — | — | US | disclosed |
| US-20060199956-A1 | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-09-07 | — | — | US | disclosed |
| US-20050267105-A1 | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050019424-A1 | Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives | KDR, FLT4, FLT1 | KIT 44/4885PDGFRB 7/4885FLT4 2/4885 |
| US-20060199956-A1 | Bicyclic heterocycles as HIV integrase inhibitors | CCNI, TYMP, IMPDH1 | KIT 951/4885PDGFRB 2678/4885FLT4 3215/4885 |
| US-20060276466-A1 | Bicyclic heterocycles as HIV integrase inhibitors | CCNI, TYMP, IMPDH1 | KIT 951/4885PDGFRB 2678/4885FLT4 3215/4885 |
| US-20050267105-A1 | Bicyclic heterocycles as HIV integrase inhibitors | CCNI, TYMP, IMPDH1 | KIT 951/4885PDGFRB 2678/4885FLT4 3215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.